Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eva González-Suárez is active.

Publication


Featured researches published by Eva González-Suárez.


The EMBO Journal | 2001

Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes

Eva González-Suárez; Enrique Samper; Angel Ramírez; Juana M. Flores; Juan Martín-Caballero; José L. Jorcano; Maria A. Blasco

Telomerase transgenics are an important tool to assess the role of telomerase in cancer, as well as to evaluate the potential use of telomerase for gene therapy of age‐associated diseases. Here, we have targeted the expression of the catalytic component of mouse telomerase, mTERT, to basal keratinocytes using the bovine keratin 5 promoter. These telomerase‐transgenic mice are viable and show histologically normal stratified epithelia with high levels of telomerase activity and normal telomere length. Interestingly, the epidermis of these mice is highly responsive to the mitogenic effects of phorbol esters, and it is more susceptible than that of wild‐type littermates to the development skin tumors upon chemical carcinogenesis. The epidermis of telomerase‐transgenic mice also shows an increased wound‐healing rate compared with wild‐type littermates. These results suggest that, contrary to the general assumption, telomerase actively promotes proliferation in cells that have sufficiently long telomeres and unravel potential risks of gene therapy for age‐associated diseases based on telomerase upregulation.


Cancer Research | 2012

RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis

Marta Palafox; Irene Ferrer; Pasquale Pellegrini; Sergi Vila; Sara Hernandez-Ortega; Ander Urruticoechea; Fina Climent; María Teresa Soler; Purificación Muñoz; Francesc Viñals; Mark E. Tometsko; Dan Branstetter; William C. Dougall; Eva González-Suárez

Paracrine signaling through receptor activator of NF-κB (RANK) pathway mediates the expansion of mammary epithelia that occurs during pregnancy, and activation of RANK pathway promotes mammary tumorigenesis in mice. In this study we extend these previous data to human cells and show that the RANK pathway promotes the development of mammary stem cells and breast cancer. Overexpression of RANK (FL-RANK) in a panel of tumoral and normal human mammary cells induces the expression of breast cancer stem and basal/stem cell markers. High levels of RANK in untransformed MCF10A cells induce changes associated with both stemness and transformation, including mammary gland reconstitution, epithelial-mesenchymal transition (EMT), increased migration, and anchorage-independent growth. In addition, spheroids of RANK overexpressing MCF10A cells display disrupted acinar formation, impair growth arrest and polarization, and luminal filling. RANK overexpression in tumor cells with nonfunctional BRCA1 enhances invasiveness in acinar cultures and increases tumorigenesis and metastasis in immunodeficient mice. High levels of RANK were found in human primary breast adenocarcinomas that lack expression of the hormone receptors, estrogen and progesterone, and in tumors with high pathologic grade and proliferation index; high RANK/RANKL expression was significantly associated with metastatic tumors. Together, our findings show that RANK promotes tumor initiation, progression, and metastasis in human mammary epithelial cells by increasing the population of CD44(+)CD24(-) cells, inducing stemness and EMT. These results suggest that RANK expression in primary breast cancer associates with poor prognosis.


Molecular and Cellular Biology | 2007

RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini

Eva González-Suárez; Daniel Branstetter; Allison Armstrong; Huyen Dinh; Hal Blumberg; William C. Dougall

ABSTRACT RANK and RANKL, the key regulators of osteoclast differentiation and activation, also play an important role in the control of proliferation and differentiation of mammary epithelial cells during pregnancy. Here, we show that RANK protein expression is strictly regulated in a spatial and temporal manner during mammary gland development. RANK overexpression under the control of the mouse mammary tumor virus (MMTV) promoter in a transgenic mouse model results in increased mammary epithelial cell proliferation during pregnancy, impaired differentiation of lobulo-alveolar structures, decreased expression of the milk proteins β-casein and whey acidic protein, and deficient lactation. We also show that treatment of three-dimensional in vitro cultures of primary mammary cells from MMTV-RANK mice with RANKL results in increased proliferation and decreased apoptosis in the luminal area, resulting in bigger acini with filled lumens. Taken together, these results suggest that signaling through RANK not only promotes proliferation but also inhibits the terminal differentiation of mammary epithelial cells. Moreover, the increased proliferation and survival observed in a three-dimensional culture system suggests a role for aberrant RANK signaling during breast tumorigenesis.


Nature Reviews Cancer | 2017

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T. Byrne; Denis Alferez; Frédéric Amant; Daniela Annibali; J. Arribas; Andrew V. Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K. Chang; Robert B. Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S. Gail Eckhardt; Eva González-Suárez; Els Hermans; Manuel Hidalgo; Monika A. Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild M. Mælandsmo; Elisabetta Marangoni; Jean Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G. Pálmer; Daniel S. Peeper

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.


Oncogene | 2005

Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice.

Eva González-Suárez; Christoph Geserick; Juana M. Flores; Maria A. Blasco

Many degenerative diseases that occur with aging, as well as premature aging syndromes, are characterized by presenting cells with critically short telomeres. Telomerase reintroduction is envisioned as a putative therapy for diseases characterized by telomere exhaustion. K5-mTert transgenic mice overexpress telomerase in a wide spectrum of tissues. These mice have a higher incidence of both induced and spontaneous tumors, resulting in increased mortality during the first year of life. Here, we show that in spite of this elevated tumor incidence and the initial lower survival, K5-mTert mice show an extension of the maximum lifespan from 1.5 to 3 months, depending on the transgenic line, which represents up to a 10% increase in the mean lifespan compared to wild-type littermates. This longer lifespan is coincidental with a lower incidence of certain age-related degenerative diseases, mainly those related to kidney function and germline integrity. Importantly, these effects of telomerase overexpression cannot be attributed to dramatic differences in telomere length in aged K5-Tert mice compared to wild-type mice, as shown by quantitative telomeric FISH. These findings indicate that telomerase overexpression extends the maximum lifespan of mice.


Molecular and Cellular Biology | 2002

Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development.

Eva González-Suárez; Juana M. Flores; Maria A. Blasco

ABSTRACT Telomerase reintroduction in adult somatic tissues is envisioned as a way to extend their proliferative capacity. It is still a question, however, whether constitutive telomerase expression in adult tissues impacts the normal aging and spontaneous cancer incidence of an organism. Here, we studied the aging and spontaneous cancer incidence of mice with transgenic telomerase expression in a wide range of adult tissues, K5-Tert mice. For this, we maintained large colonies of K5-Tert mice for more than 2 years. K5-Tert mice showed a decreased life span compared to wild-type cohorts associated with a higher incidence of preneoplastic and neoplastic lesions in various tissue types. Neoplasias in K5-Tert mice were coincident with transgene expression in the affected tissues. These observations suggest that high telomerase activity may cooperate with genetic alterations that occur with age to promote tumorigenesis. Indeed, we demonstrate here that increased cancer incidence and the reduced viability of K5-Tert mice are aggravated in a p53+/− genetic background, indicating that telomerase cooperates with loss of p53 function in inducing tumorigenesis. Altogether, these results demonstrate that constitutive high levels of telomerase activity result in a decreased life span associated with an increased incidence of neoplasias as the organism ages.


Oncogene | 2006

Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor- β signaling

Christoph Geserick; A Tejera; Eva González-Suárez; P Klatt; Maria A. Blasco

Here, we show that ectopic expression of the catalytic subunit of mouse telomerase (mTert) confers a growth advantage to primary murine embryonic fibroblasts (MEFs), which have very long telomeres, as well as facilitates their spontaneous immortalization and increases their colony-forming capacity upon activation of oncogenes. We demonstrate that these telomere length-independent growth-promoting effects of mTert overexpression require catalytically active mTert, as well as the formation of mTert/Terc complexes. The gene expression profile of mTert-overexpressing MEFs indicates that telomerase enhances growth in these cells through the repression of growth-inhibiting genes of the transforming growth factor-beta (TGF-β) signaling network. We functionally validate this result by showing that mTert abrogates the growth-inhibitory effect of TGF-β in MEFs, thus demonstrating that telomerase increments the proliferative potential of primary mouse embryonic fibroblasts by targeting the TGF-β pathway.


Cell Reports | 2014

Linkage of DNA methylation quantitative trait loci to human cancer risk.

Holger Heyn; Sergi Sayols; Catia Moutinho; Enrique Vidal; Jose V. Sanchez-Mut; Olafur A. Stefansson; Ernest Nadal; Sebastian Moran; Jorunn E. Eyfjörd; Eva González-Suárez; Miguel Angel Pujana; Manel Esteller

Epigenetic regulation and, in particular, DNA methylation have been linked to the underlying genetic sequence. DNA methylation quantitative trait loci (meQTL) have been identified through significant associations between the genetic and epigenetic codes in physiological and pathological contexts. We propose that interrogating the interplay between polymorphic alleles and DNA methylation is a powerful method for improving our interpretation of risk alleles identified in genome-wide association studies that otherwise lack mechanistic explanation. We integrated patient cancer risk genotype data and genome-scale DNA methylation profiles of 3,649 primary human tumors, representing 13 solid cancer types. We provide a comprehensive meQTL catalog containing DNA methylation associations for 21% of interrogated cancer risk polymorphisms. Differentially methylated loci harbor previously reported and as-yet-unidentified cancer genes. We suggest that such regulation at the DNA level can provide a considerable amount of new information about the biology of cancer-risk alleles.


Cell Research | 2016

RANKL/RANK control Brca1 mutation-driven mammary tumors

Verena Sigl; Kwadwo Owusu-Boaitey; Purna A. Joshi; Anoop Kavirayani; Gerald Wirnsberger; Maria Novatchkova; Ivona Kozieradzki; Daniel Schramek; Nnamdi Edokobi; Jerome Hersl; Aishia Sampson; Ashley Odai-Afotey; Conxi Lázaro; Eva González-Suárez; Miguel Angel Pujana; for Cimba; Holger Heyn; Enrique Vidal; Jennifer Cruickshank; Hal K. Berman; Melita Ticevic; Iris Uribesalgo; Luigi Tortola; Shuan Rao; Yen Y. Tan; Georg Pfeiler; Eva Y.-H. P. Lee; Zsuzsanna Bago-Horvath; Lukas Kenner; Helmuth Popper

Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations in the breast cancer 1 (BRCA1) or BRCA2 genes markedly increase the risk for the development of breast cancer. Here, using two different mouse models, we show that genetic inactivation of the key osteoclast differentiation factor RANK in the mammary epithelium markedly delayed onset, reduced incidence, and attenuated progression of Brca1;p53 mutation-driven mammary cancer. Long-term pharmacological inhibition of the RANK ligand RANKL in mice abolished the occurrence of Brca1 mutation-driven pre-neoplastic lesions. Mechanistically, genetic inactivation of Rank or RANKL/RANK blockade impaired proliferation and expansion of both murine Brca1;p53 mutant mammary stem cells and mammary progenitors from human BRCA1 mutation carriers. In addition, genome variations within the RANK locus were significantly associated with risk of developing breast cancer in women with BRCA1 mutations. Thus, RANKL/RANK control progenitor cell expansion and tumorigenesis in inherited breast cancer. These results present a viable strategy for the possible prevention of breast cancer in BRCA1 mutant patients.


Cancer Research | 2014

A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition

F. Javier Carmona; Veronica Davalos; Enrique Vidal; Antonio Gomez; Holger Heyn; Yutaka Hashimoto; Miguel Vizoso; Anna Martínez-Cardús; Sergi Sayols; Humberto J. Ferreira; Jose V. Sanchez-Mut; Sebastian Moran; Mireia Margelí; Eva Castella; María Berdasco; Olafur A. Stefansson; Jorunn E. Eyfjörd; Eva González-Suárez; Joaquín Dopazo; Modesto Orozco; Ivo Gut; Manel Esteller

Epithelial-to-mesenchymal transition (EMT) is a plastic process in which fully differentiated epithelial cells are converted into poorly differentiated, migratory and invasive mesenchymal cells, and it has been related to the metastasis potential of tumors. This is a reversible process and cells can also eventually undergo mesenchymal-to-epithelial transition. The existence of a dynamic EMT process suggests the involvement of epigenetic shifts in the phenotype. Herein, we obtained the DNA methylomes at single-base resolution of Madin-Darby canine kidney cells undergoing EMT and translated the identified differentially methylated regions to human breast cancer cells undergoing a gain of migratory and invasive capabilities associated with the EMT phenotype. We noticed dynamic and reversible changes of DNA methylation, both on promoter sequences and gene-bodies in association with transcription regulation of EMT-related genes. Most importantly, the identified DNA methylation markers of EMT were present in primary mammary tumors in association with the epithelial or the mesenchymal phenotype of the studied breast cancer samples.

Collaboration


Dive into the Eva González-Suárez's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria A. Blasco

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Holger Heyn

Pompeu Fabra University

View shared research outputs
Top Co-Authors

Avatar

Juana M. Flores

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Ander Urruticoechea

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Jordi Serra-Musach

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar

Enrique Samper

Spanish National Research Council

View shared research outputs
Researchain Logo
Decentralizing Knowledge